Genmab A (GMAB) Receivables (2023 - 2025)

Genmab A has reported Receivables for 3 years, with the latest figure at $2.2 billion in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 129.42% year-over-year to $2.2 billion; the trailing twelve-month figure through Dec 2025 stood at $2.2 billion (up 129.42% YoY), and the FY2025 full-year result was $1.2 billion, up 22.17% from the prior year.
• Receivables for Q4 2025 stood at $2.2 billion, up from $979.0 million in the prior quarter.
• The five-year high for Receivables was $2.2 billion in Q4 2025, with the low at $786.0 million in Q4 2023.
• Historically, Receivables has averaged $1.3 billion across 3 years, with a median of $979.0 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables rose 24.55% — and 2025, when it soared 129.42%.
• Genmab A's Receivables stood at $786.0 million in 2023, then rose by 24.55% to $979.0 million in 2024, then surged by 129.42% to $2.2 billion in 2025.
• The last three Receivables figures came in at $2.2 billion (Q4 2025), $979.0 million (Q4 2024), and $786.0 million (Q4 2023), per Business Quant data.